These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33272531)

  • 21. Phenotyping of hypertensive heart disease and hypertrophic cardiomyopathy using personalized 3D modelling and cardiac cine MRI.
    Chuah SH; Md Sari NA; Chew BT; Tan LK; Chiam YK; Chan BT; Lim E; Abdul Aziz YF; Liew YM
    Phys Med; 2020 Oct; 78():137-149. PubMed ID: 33007738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Texture analysis of T2-weighted cardiovascular magnetic resonance imaging to discriminate between cardiac amyloidosis and hypertrophic cardiomyopathy.
    Huang S; Shi K; Zhang Y; Yan WF; Guo YK; Li Y; Yang ZG
    BMC Cardiovasc Disord; 2022 May; 22(1):235. PubMed ID: 35597906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CMR-based T1-mapping offers superior diagnostic value compared to longitudinal strain-based assessment of relative apical sparing in cardiac amyloidosis.
    Korthals D; Chatzantonis G; Bietenbeck M; Meier C; Stalling P; Yilmaz A
    Sci Rep; 2021 Jul; 11(1):15521. PubMed ID: 34330967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease.
    Hayashi S; Yamada H; Nishio S; Hotchi J; Bando M; Takagawa Y; Saijo Y; Hirata Y; Sata M
    J Cardiol; 2015 Jun; 65(6):519-25. PubMed ID: 25199979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of myocardial extracellular volume fraction evaluation based on cardiac magnetic resonance T1 mapping with T1 long and short in hypertrophic cardiomyopathy.
    Li Y; Liu X; Yang F; Wang J; Xu Y; Fang T; Pu L; Zhou X; Han Y; Chen Y
    Eur Radiol; 2021 Jul; 31(7):4557-4567. PubMed ID: 33449190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.
    Xu J; Zhuang B; Sirajuddin A; Li S; Huang J; Yin G; Song L; Jiang Y; Zhao S; Lu M
    Radiology; 2020 Feb; 294(2):275-286. PubMed ID: 31769741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevalence and predictors of asymmetric hypertensive heart disease: insights from cardiac and aortic function with cardiovascular magnetic resonance.
    Rodrigues JC; Amadu AM; Dastidar AG; Hassan N; Lyen SM; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Heart J Cardiovasc Imaging; 2016 Dec; 17(12):1405-1413. PubMed ID: 26705488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance.
    Maragiannis D; Alvarez PA; Ghosn MG; Chin K; Hinojosa JJ; Buergler JM; Shah DJ; Nagueh SF
    Int J Cardiovasc Imaging; 2018 Jan; 34(1):121-129. PubMed ID: 28748418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.
    Takeda M; Amano Y; Tachi M; Tani H; Mizuno K; Kumita S
    Jpn J Radiol; 2013 Oct; 31(10):693-700. PubMed ID: 23996116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Left ventricular structure and diastolic function by cardiac magnetic resonance imaging in hypertrophic cardiomyopathy.
    Chacko BR; Karur GR; Connelly KA; Yan RT; Kirpalani A; Wald R; Jimenez-Juan L; Jacob JR; Deva DP; Yan AT
    Indian Heart J; 2018; 70(1):75-81. PubMed ID: 29455792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertrophic cardiomyopathy is associated with more severe left ventricular dyssynchrony than is hypertensive left ventricular hypertrophy.
    Nagakura T; Takeuchi M; Yoshitani H; Nakai H; Nishikage T; Kokumai M; Otani S; Yoshiyama M; Yoshikawa J
    Echocardiography; 2007 Aug; 24(7):677-84. PubMed ID: 17651095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hypertrophic cardiomyopathy with dilatation of the left ventricle and congestive heart failure: comparison with postmyocarditis cardiomegaly and hypertensive heart failure].
    Kawanishi H; Yokota Y; Hayakawa M; Kaku K; Kumaki T; Matsumoto K; Fujitani K; Ito Y; Inoh T; Fukuzaki H
    J Cardiogr; 1983 Sep; 13(3):537-50. PubMed ID: 6235295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Significance of Interstitial Fibrosis on Left Ventricular Function in Hypertensive versus Hypertrophic Cardiomyopathy.
    Jiang M; Wang Z; Su X; Gong X; Pu J; Wu L; Liu C; Yao Q; Kong L; Xu J; He B
    Sci Rep; 2018 Jul; 8(1):9995. PubMed ID: 29968754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy: tissue remodeling manifested prior to structure changes.
    Huang L; Ran L; Zhao P; Tang D; Han R; Ai T; Xia L; Tao Q
    Br J Radiol; 2019 Dec; 92(1104):20190634. PubMed ID: 31613647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Image and DNA analysis of hypertrophic myocytes in hypertensive heart disease and hypertrophic cardiomyopathy.
    Takeda A; Sakata A; Takeda N
    Anal Quant Cytol Histol; 1999 Oct; 21(5):454-7. PubMed ID: 10560530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intelligent diagnosis of left ventricular hypertrophy using transthoracic echocardiography videos.
    Xu Z; Yu F; Zhang B; Zhang Q
    Comput Methods Programs Biomed; 2022 Nov; 226():107182. PubMed ID: 36257197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Cardiac Magnetic Resonance Feature Tracking (CMR-FT) Analysis for Detection of Myocardial Fibrosis in Pediatric Hypertrophic Cardiomyopathy.
    Bogarapu S; Puchalski MD; Everitt MD; Williams RV; Weng HY; Menon SC
    Pediatr Cardiol; 2016 Apr; 37(4):663-73. PubMed ID: 26833321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-parametric non-contrast cardiac magnetic resonance for the differentiation between cardiac amyloidosis and hypertrophic cardiomyopathy.
    Steen H; Montenbruck M; Kallifatidis A; André F; Frey N; Kelle S; Korosoglou G
    Clin Res Cardiol; 2024 Mar; 113(3):469-480. PubMed ID: 38095711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered regional myocardial velocities by tissue phase mapping and feature tracking in pediatric patients with hypertrophic cardiomyopathy.
    Li A; Ruh A; Berhane H; Robinson JD; Markl M; Rigsby CK
    Pediatr Radiol; 2020 Feb; 50(2):168-179. PubMed ID: 31659403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.